PDCD1 and neoplasm: Preclinical studies in mIDH1-driven tumor models have shown that Ivosidenib restores IFN-γ sensitivity while inducing compensatory immune suppression, including PD-L1 upregulation, increased PD-1 and CTLA4 expression on CD8+ T cells, and Treg recruitment [99].